Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Vaping 1Uterine Cervical Dysplasia 1Smoking Cessation 1Pain 1Nevus, Spindle Cell 1Nevus, Pigmented 1Nevus, Epithelioid and Spindle Cell 1Nevus, Blue 1Nevus 1Neoplasms 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Dysplastic Nevus Syndrome 1Cutaneous Squamous Cell Carcinoma 1Breast Neoplasms 1Agnosia 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms × Transdermal Patch × Clear all
NCT00644787 2013-06-13

A Dose-Finding Study of Fentanyl (JNS020 QD) 1-Day Transdermal Patch in Participants With Cancer Pain

Janssen Pharmaceutical K.K.

Phase 2/3 Completed
156 enrolled 14 charts

Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡